NeoGenomics Inc (NEO):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:NeoGenomics Inc (NEO) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C6602
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:43
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NeoGenomics Inc (NeoGenomics) is a cancer diagnostics and pharma services company that offers diagnostic, prognostic and predictive testing services. The company offers testing services with various technologies such as cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry; and molecular genetics including sanger sequencing and fragment analysis. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services for detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations, and others. NeoGenomics provides biopharma services which supports drug development programs from early biomarker discovery to clinical trials. The company serves oncologists, pathologists, pharmaceutical companies, academic centers, and others. NeoGenomics is headquartered in Fort Myers, Florida, the US.

NeoGenomics Inc (NEO) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
NeoGenomics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
NeoGenomics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
NeoGenomics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
NeoGenomics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
NeoGenomics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
NeoGenomics Inc, Medical Equipment, Deal Details 11
Partnerships 11
Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 11
Health Discovery Enters Into Licensing Agreement With NeoGenomics 12
NeoGenomics and Definiens Enter into Agreement 13
Arno Therapeutics Enters Into Co-Development Agreement With Clarient Diagnostic Services 14
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 15
Equity Offering 16
NeoGenomics Prices Public Offering of Shares for USD125 Million 16
NeoGenomics Raises USD37 Million in Public Offering of Shares 18
NeoGenomics Completes Public Offering Of Shares For US$10 Million 20
Acquisition 21
NeoGenomics Acquires Clarient from GE Healthcare 21
NeoGenomics Inc – Key Competitors 23
NeoGenomics Inc – Key Employees 24
NeoGenomics Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 27
Strategy And Business Planning 27
Jun 01, 2018: PPD and NeoGenomics Forming Global Strategic Alliance for Pathology and Molecular Testing Solutions 27
Nov 09, 2017: NeoGenomics Europe Opens its Doors in Rolle, Switzerland Laboratory Hosting Business Leaders, Dignitaries and Local Government Officials 28
Financial Announcements 29
Jul 24, 2018: NeoGenomics reports record revenue of $67.7 million with 14% increase in clinical volume growth and 95% increase in pharma services backlog 29
May 01, 2018: NeoGenomics Reports Revenue of $63.4 Million, Net Income of $0.6 Million and Adjusted EBITDA of $9.2 Million in the First Quarter of 2018 31
Feb 21, 2018: NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017 33
Jul 25, 2017: NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 34
Apr 26, 2017: NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 35
Feb 22, 2017: NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 37
Corporate Communications 39
Mar 20, 2018: NeoGenomics Announces Executive Appointments 39
Apr 20, 2017: NeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development 40
Product News 41
Sep 24, 2018: NeoGenomics announces participation in NCI-MATCH clinical trial 41
Jun 02, 2017: NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests 42
Appendix 43
Methodology 43
About GlobalData 43
Contact Us 43
Disclaimer 43

List of Tables
NeoGenomics Inc, Medical Equipment, Key Facts, 2017 2
NeoGenomics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
NeoGenomics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
NeoGenomics Inc, Medical Equipment Deals By Type, 2012 to YTD 2018 7
NeoGenomics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
NeoGenomics Inc, Deals By Market, 2012 to YTD 2018 9
NeoGenomics Inc, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 11
Health Discovery Enters Into Licensing Agreement With NeoGenomics 12
NeoGenomics and Definiens Enter into Agreement 13
Arno Therapeutics Enters Into Co-Development Agreement With Clarient Diagnostic Services 14
Qiagen Enters Into Agreement With Clarient To Offer therascreen KRAS RGQ PCR Kit 15
NeoGenomics Prices Public Offering of Shares for USD125 Million 16
NeoGenomics Raises USD37 Million in Public Offering of Shares 18
NeoGenomics Completes Public Offering Of Shares For US$10 Million 20
NeoGenomics Acquires Clarient from GE Healthcare 21
NeoGenomics Inc, Key Competitors 23
NeoGenomics Inc, Key Employees 24
NeoGenomics Inc, Other Locations 25
NeoGenomics Inc, Subsidiaries 26

List of Figures
NeoGenomics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
NeoGenomics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
NeoGenomics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
NeoGenomics Inc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
NeoGenomics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
NeoGenomics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
NeoGenomics Inc, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
NeoGenomics Inc, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[NeoGenomics Inc (NEO):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BNP Paribas SA:企業の戦略・SWOT・財務情報
    BNP Paribas SA - Strategy, SWOT and Corporate Finance Report Summary BNP Paribas SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Public Bank Berhad:戦略・SWOT・企業財務分析
    Public Bank Berhad - Strategy, SWOT and Corporate Finance Report Summary Public Bank Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Seair, Inc. (SDS)-石油・ガス分野:企業M&A・提携分析
    Summary Seair, Inc. (Seair) is a clean technology company that carries out research and development, production and sale of diffusion and sterilization technologies. It focuses on commercializing advanced waste water and industrial fluid treatment solutions. The company offers high performance propr …
  • Seoul National University Hospital:製薬・医療:M&Aディール及び事業提携情報
    Summary Seoul National University Hospital (SNUH) is a healthcare service provider. It operates as the representative medical center of Korea. The hospital focuses on raising the standards of nation’s healthcare system, medical education, research and patient care. It offers services such as outpati …
  • Medica Corp:企業の製品パイプライン分析2018
    Summary Medica Corp (Medica) is a medical device company that manufactures and markets in-vitro diagnostic blood testing analyzers. The company’s products comprise clinical chemistry analyzers, electrolyte analyzers, blood gas analyzers, and hematology analyzers, and OEM ISE modules. Medica’s produc …
  • TV Asahi Corporation (9409):企業の財務・戦略的SWOT分析
    TV Asahi Corporation (9409) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Reliance Worldwide Corporation Ltd (RWC):企業の財務・戦略的SWOT分析
    Reliance Worldwide Corporation Ltd (RWC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Alcon Laboratories Inc:企業の戦略的SWOT分析
    Alcon Laboratories Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • MediciNova Inc (MNOV)-製薬・医療分野:企業M&A・提携分析
    Summary MediciNova Inc (MediciNova) is a biopharmaceutical company, which focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurology, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs such as MN-001, for the treatm …
  • Nippon Paint Holdings Co Ltd (4612):企業の財務・戦略的SWOT分析
    Nippon Paint Holdings Co Ltd (4612) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • CASIO COMPUTER CO., LTD.:企業の戦略・SWOT・財務情報
    CASIO COMPUTER CO., LTD. - Strategy, SWOT and Corporate Finance Report Summary CASIO COMPUTER CO., LTD. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Eaton Corporation Plc (ETN):電力:M&Aディール及び事業提携情報
    Summary Eaton Corporation Plc (Eaton) is a power management company. It designs, develops, and sells products and services, which help customers manage electrical, hydraulic and mechanical power more reliably, efficiently, safely, and sustainably. Eaton serves customers in the utility, governmental, …
  • CTI BioPharma Corp (CTIC):製薬・医療:M&Aディール及び事業提携情報
    Summary CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company, which acquires, develops, and commercializes targeted therapies for a range of blood-related cancers. The company’s lead product, Pixuvri (pixantrone) is an aza-anthracenedione used for the treatment of multiply relapsed or r …
  • The Kansai Electric Power Co Inc (9503):電力:M&Aディール及び事業提携情報
    Summary The Kansai Electric Power Co Inc (KEPCo) is an integrated power utility. It produces and supplies electricity and thermal energy; and procures and sells natural gas. The company generates electricity using natural gas, nuclear, coal, oil, wind, hydro, and solar sources. Through long, medium, …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Madalena Energy Inc (MVN):石油・ガス:M&Aディール及び事業提携情報
    Summary Madalena Energy Inc (Madalena Energy) is an oil and gas company that provides domestic and international upstream oil and gas exploration services. The company acquires, explores, operates, manages, produces, and develops natural gas, crude oil, and natural gas liquids. Its oil and gas prope …
  • Alnylam Pharmaceuticals Inc (ALNY):医療機器:M&Aディール及び事業提携情報
    Summary Alnylam Pharmaceuticals Inc (Alnylam) is a biopharmaceutical company which discovers, develops and commercializes therapeutics based on Ribo Nucleic Acid interference (RNAi). The company offers a broad pipeline of investigational RNAi therapeutics in the areas of genetic medicines, hepatic i …
  • ContourGlobal plc (GLO):電力:M&Aディール及び事業提携情報
    Summary ContourGlobal plc (ContourGlobal) formerly ContourGlobal Ltd, is an energy company. It develops, acquires, owns, and operates wholesale power generation assets under long-term contracts. The company creates asset by taking them through the permitting, financing, and construction processes, a …
  • EMCORE Corporation (EMKR):企業の財務・戦略的SWOT分析
    EMCORE Corporation (EMKR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆